Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors.
Shaohua LiaoChuanfen LiXiaoying BiHongwei GuoYing QianXiaobei LiuShuai MiaoHuaiqiang HuBingzhen CaoPublished in: Journal of neuroinflammation (2021)
Most patients with ANAS had a relatively good prognosis. Having tumours and a chronic onset were both associated with poor outcomes. CSF BAFF and the ratio of serum TGFβ1/serum CXCL13 were associated with relapses.